128 results on '"Nordenskjöld, Bo"'
Search Results
2. Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
3. Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
4. Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer - data from the randomized SBII:2 trial
5. Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
6. Supplementary Figures 1-3 from ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer
7. Data from Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
8. Supplementary Data from Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
9. Data from Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
10. Supplementary Data from Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
11. Abstract P2-03-04: Long-Term Benefit from Adjuvant Tamoxifen in Luminal A and Luminal B Breast Cancer Patients
12. Abstract P3-05-03: Long-term survival and intra-tumor heterogeneity of progesterone receptor expression in estrogen receptor-positive/progesterone receptor-positive premenopausal women with breast cancer
13. Abstract P2-03-11: Differential Long-Term Benefit from Adjuvant Tamoxifen Therapy in Estrogen Receptor (ER)-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Premenopausal and Postmenopausal Breast Cancer Patients
14. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial
15. PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients
16. Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature
17. Abstract PD9-05: Prognostic and tamoxifen-predictive effect of PAM50 and ROR score in premenopausal women included in the randomised SBII:2 trial
18. Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy
19. IP6K2 predicts favorable clinical outcome of primary breast cancer
20. Abstract PS5-09: Tumour infiltrating lymphocytes of prognostic value in different molecular breast cancer subgroups and as a suggestive predictive factor for adjuvant tamoxifen benefit in premenopausal patients after 30 years follow-up
21. MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit
22. Clinical and Molecular Characteristics of ER-Positive Breast Cancer Tumors Identified as Ultralow Risk by the 70-Gene Signature in a Randomized Clinical Trial
23. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up
24. Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer
25. The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype
26. PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer
27. Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial
28. Long-term benefit from tamoxifen therapy for patients with Luminal A and Luminal B breast cancer: Retrospective analysis of the STO-3 trial.
29. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
30. Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades
31. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk
32. Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
33. Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial
34. ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer
35. Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
36. Final 10-year results of the Breast International Group 2–98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer
37. Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer
38. Abstract P1-12-17: Mature data (> 25 years) on 2 years adjuvant tamoxifen treatment in premenopausal women with breast cancer: Time to re-emphasize the progesterone receptor as predictive factor?
39. S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts
40. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer
41. C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
42. Abstract B251: Androgen receptor expression can predict benefit of tamoxifen treatment in patients with ER negative breast cancer.
43. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials
44. Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer
45. Abstract 427: c-Met reduces response to radiation in breast cancer.
46. Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
47. Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients
48. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
49. 17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer
50. Abstract B59: MET gene copy number related to radiation treatment response and prognosis in breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.